2024
1H25 Interim Results: Medicare Coverage Catalysts in Focus
Pacific Edge today announces steady financial performance for the six months to the end of September 2024 as it awaits the outcome of several events that have the potential to renew growth in Cxbladder test volume and revenue. [read more]
Interim Financial Results to Be Announced 26 November
Pacific Edge today advises that its half year results for the six months ending 30 September 2024 will be released on Tuesday 26 November 2024, prior to 10am. [read more]
Cxbladder Detect+ Now Named Cxbladder Triage Plus
Pacific Edge today announces it has adopted the brand name Cxbladder Triage Plus for its next generation urine-biomarker test. [read more]
Real World Evidence for Cxbladder to Feature at WSAUA
New data demonstrating the clinical and economic value of Pacific Edge’s Cxbladder cancer diagnostic tests will be in the spotlight at the 100th annual meeting for the Western Section of the American Urological Association (WSAUA) in Kauai, Hawaii. [read more]
Pacific Edge Releases Quarterly Volumes for Q2 FY25
Pacific Edge today announces tests processed at its laboratories in the three months to the end of September 2024 (Q2 25) were slightly lower on the prior quarter (Q1 25). [read more]
Pacific Edge 2024 Annual Shareholders Meeting
Pacific Edge is holding its Annual Shareholders Meeting in Auckland this afternoon. It attaches Chairman Chris Gallaher’s speech notes and the company’s presentation for shareholders. [read more]
Pacific Edge 2024 Annual Shareholders Meeting – Results
Pacific Edge confirms that the 3 resolutions proposed in the Notice of Meeting were considered and passed. [read more]
AUA Micro-Hematuria Guideline and Medicare Timelines
Pacific Edge today notes the American Urological Association (AUA) is seeking urologist feedback on a draft standard of care guideline for the evaluation of microhematuria. The consultation is taking place under strict conditions of non-disclosure with the process commencing after 15 September 2024. [read more]
Pacific Edge Chairman Delays Retirement
Pacific Edge today announces Chris Gallaher has accepted a Board request to delay his planned retirement, originally set for the end of this year after a handover to a successor. [read more]
Pacific Edge on the Podium at UAA in Bali
Pacific Edge CEO to present data from its recently published STRATA study at the Urological Association of Asia (UAA) Congress and attended signing event for lab partnership agreement in Malaysia. [read more]
Notice of Annual Shareholders Meeting
Notice is hereby given that the 2024 Annual Shareholders Meeting of Pacific Edge Limited will be held in Auckland and online on Tuesday 24 September, commencing at 1.00pm. [read more]
AUA Journal of Urology Editorial Supports Cxbladder
Pacific Edge welcomes an editorial in the American Urological Association’s Journal of Urology supporting the use of Cxbladder to reduce unnecessary cystoscopies on patients at risk of bladder cancer. [read more]
Novitas Confirms Medicare Coverage Review Extension
Pacific Edge notes that Novitas, the Medicare Administrative Contractor (MAC) with responsibility for Pacific Edge’s US lab, has confirmed that it has been granted an extension to finalize or withdraw the Local Coverage Determination (LCD) ‘Genetic Testing for Oncology’ (DL 39365). [read more]
Medicare Coverage Determination Still Under Review
Pacific Edge notes that Novitas, the Medicare Administrative Contractor (MAC) with responsibility for Pacific Edge’s US lab, remains in discussion with the Centers for Medicare & Medicaid Services (CMS) regarding the Local Coverage Determination (LCD) ‘Genetic Testing for Oncology’ (DL 39365). [read more]
Director Nomination Closing Date
Pacific Edge advises that its Annual Shareholder Meeting will be held on Tues 24 September from 1pm in Auckland. All nominations must be received by 4.00pm on the closing date, 30 July. [read more]
Cxbladder Test Volumes Steady in Q1 25
Pacific Edge today announces tests processed at its laboratories in the three months to the end of June 2024 were steady on the prior quarter (Q4 24) as we continued to benefit from improved performance from a lean sales force in the US, an acceleration of demand in New Zealand and sustained growth from Kaiser Permanente. [read more]
Pacific Edge Annual Report
Pacific Edge is pleased to present its Annual Report for the year to the 31st March 2024. [read more]
FY24 Results: Cash Burn Slows; Coverage Catalysts in Focus
Pacific Edge today reports successful execution of strategic initiatives to focus the company on the development of its advanced cancer diagnostic tests for inclusion in clinical guidelines and gaining coverage certainty from Medicare and other healthcare payers. [read more]
Full Year Result To Be Announced 21 May
Pacific Edge today advises that its full year results for the 12 months to 31 March 2024 (FY24) will be released on Tuesday 21 May 2024, prior to 10am. [read more]
Clinical Utility of Cxbladder to Headline at AUA 2024
A ground-breaking study demonstrating the clinical utility of Cxbladder is to be the centrepiece of Pacific Edge’s activities at the 2024 American Urological Association (AUA) Annual Meeting to be held May 3 – 6 in San Antonio, Texas. [read more]
Cxbladder Test Volumes Steady in Q4 24
Pacific Edge today announces tests processed at its laboratories in the three months to the end of March 2024 were steady on the prior quarter. [read more]
Pacific Edge Directors Give Notice of Retirement
Pacific Edge today announces the retirement of Chair Chris Gallaher and Non-Executive Director Mark Green. [read more]
Cxbladder Test Volumes Fall Following Restructure
Pacific Edge today announces tests processed at its laboratories weakened in the three months to the end of 31 December 2023, with the fall largely reflecting the reduction of the Commercial team in Q2 24. [read more]
View our Calendar of Events
We welcome press and media enquiries. For further assistance, please feel free to contact us.